Yoshi Innovation Spolka Akcyjna
0.69
PLN
-0.01
(-1.71%)
ISIN
PLACREO00019
Return %
Stock
S&P 500
1Y
-70.34
14.20
3Y
-40.69
81.12
5Y
-81.20
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Marcin Lukasz Sprawka
- Full Time Employees
- 7
- Sector
- Technology services
- Industry
- Information technology services
- Address
- Chorzów Poland
- IPO Date
- Aug 29, 2011
- Website
- yoshisa.pl
- Similar Companies
- Business
- Yoshi Innovation Spolka Akcyjna is a Polish technology venture and medical technology company that develops medical simulation equipment, advanced therapeutic and diagnostic solutions, and commercializes intellectual property assets for the healthcare, defense, and life sciences sectors. Founded in 2004 and headquartered in Chorzow, Poland, the company operates as an intellectual property incubator and technology accelerator, having formerly operated under the names Acreo S.A. and Acrebit S.A. before rebranding as Yoshi Innovation S.A. to focus on healthcare and defense technologies. Yoshi Innovation S.A. structures its operations across advanced medical simulator manufacturing, medical device engineering, and intellectual property consulting. The company's core product and service portfolio comprises: PhantomSkin, a proprietary line of multi-layered synthetic skin models, surgical suture training pads, Phantom Hip models, and PhantomWP gunshot and trauma simulation modules engineered for medical universities, tactical combat casualty care, and emergency rescue training; PhantomBody, modular anatomical simulators and medical training phantoms for clinical and military education; Hyperbary, therapeutic gas bath apparatuses for specialized healthcare applications; Woundscanning, advanced non-invasive imaging and diagnostic monitoring systems for chronic and non-healing wounds; Stabilobaby, a specialized diagnostic monitoring platform designed for neonatal and infant care; Mikrovolt, therapeutic and energetic devices based on plasma fission technology; and Yoshi Intellectual Property, comprehensive technology transfer services including patent valuation, intangible asset management, patent licensing, spin-off company incubation, and legal and marketing consultancy for research projects. The company targets medical universities, hospitals, emergency medical personnel, armed forces, law enforcement agencies, and technology start-ups across Poland, broader European markets, the Middle East, and North Africa. In recent major developments, Yoshi Innovation S.A. established a strategic international partnership with Swiss firm Dreyzac AG to commercialize its medical technology portfolio across Gulf Cooperation Council markets, entered into an exclusive distribution agreement covering Morocco, and signed a strategic cooperation agreement with the Industrial Development Agency to advance clinical xenotransplantation research initiatives. Concurrently, the company has pursued capital restructuring by monetizing segments of its intellectual property portfolio to reduce debt obligations, updating equity valuations for holdings including CTE Group S.A., and focusing operational capacity on high-margin medical simulation and international defense market expansions.